When should a patient with hypertriglyceridemia be referred to cardiology (e.g., triglycerides >500 mg/dL despite ≥3 months of optimal lifestyle and maximally tolerated lipid‑lowering therapy, triglycerides ≥1000 mg/dL, triglycerides ≥200 mg/dL with personal or strong family history of premature ASCVD despite statin therapy, documented ASCVD with residual triglycerides ≥150 mg/dL on high‑intensity statin, hypertriglyceridemia secondary to a genetic disorder, or intolerance to first‑line agents)?

When to Refer Patients with Hypertriglyceridemia to Cardiology

Refer patients with hypertriglyceridemia to cardiology (or a lipid specialist) when triglycerides remain ≥500 mg/dL despite ≥3 months of maximally tolerated lipid-lowering therapy and optimized lifestyle modifications, when triglycerides are ≥1000 mg/dL at any time, when there is documented ASCVD with residual triglycerides ≥150 mg/dL on high-intensity statin therapy, or when genetic hypertriglyceridemia is suspected.

Absolute Indications for Cardiology/Lipid Specialist Referral

Severe Hypertriglyceridemia Refractory to Maximal Therapy

• Triglycerides persistently ≥500 mg/dL after ≥3 months of fenofibrate (54-160 mg daily), optimized lifestyle modifications (fat restriction to 20-25% of calories, elimination of added sugars and alcohol, 5-10% weight loss), and correction of secondary causes (uncontrolled diabetes, hypothyroidism, offending medications) warrant immediate referral because the pancreatitis risk remains at approximately 14% and specialized interventions may be required. 1, 2

• Triglycerides ≥1000 mg/dL at presentation require urgent referral regardless of treatment status because the pancreatitis risk escalates dramatically at this threshold, potentially necessitating inpatient management with intravenous insulin or plasmapheresis if conservative measures fail. 1, 2, 3

Established ASCVD with Residual Hypertriglyceridemia

• Patients with documented ASCVD (prior MI, stroke, peripheral arterial disease, or coronary revascularization) who have triglycerides ≥150 mg/dL on maximally tolerated high-intensity statin therapy should be referred because they may benefit from icosapent ethyl (which demonstrated a 25% reduction in major adverse cardiovascular events in the REDUCE-IT trial, NNT=21) or other advanced therapies that require specialist oversight for optimal risk stratification and monitoring. 1, 2, 4

• Very high-risk ASCVD patients (those with recurrent ASCVD events or ASCVD with multiple high-risk conditions such as diabetes, chronic kidney disease, or familial hypercholesterolemia) who have persistent triglycerides ≥150 mg/dL despite LDL-C <70 mg/dL on statin therapy require specialist evaluation to determine if additional triglyceride-lowering therapy beyond standard care is warranted. 1, 4

Suspected Genetic or Familial Hypertriglyceridemia

• Young patients (<40 years) with severe hypertriglyceridemia (≥500 mg/dL), especially with a family history of premature ASCVD, pancreatitis, or extreme triglyceride elevations (≥1000 mg/dL), or those with xanthomas should be referred for genetic testing and specialized management because primary genetic disorders (familial chylomicronemia syndrome, familial combined hyperlipidemia, lipoprotein lipase deficiency) require distinct therapeutic approaches and family screening. 1, 2, 5

• Patients with baseline LDL-C ≥190 mg/dL not due to secondary causes who also have hypertriglyceridemia should be considered for referral, particularly if heterozygous or homozygous familial hypercholesterolemia is suspected, as these patients may require aggressive combination lipid-lowering therapy including PCSK9 inhibitors, ezetimibe, and potentially LDL apheresis. 1

Relative Indications for Cardiology/Lipid Specialist Referral

Moderate Hypertriglyceridemia with Strong Family History

• Triglycerides 200-499 mg/dL with a personal history of premature ASCVD (<55 years men, <65 years women) or a strong family history of premature ASCVD in first-degree relatives despite statin therapy warrant referral because these patients have residual cardiovascular risk that may benefit from advanced risk stratification (coronary calcium scoring, apolipoprotein B measurement) and consideration of icosapent ethyl or other adjunctive therapies. 1, 2

Intolerance to First-Line Agents

• Patients who cannot tolerate statins (due to confirmed statin-associated muscle symptoms with elevated CK, severe myalgias limiting daily activities, or rhabdomyolysis) and have triglycerides ≥200 mg/dL with elevated cardiovascular risk should be referred because alternative LDL-lowering strategies (bempedoic acid, ezetimibe, PCSK9 inhibitors, inclisiran) combined with triglyceride management require specialist expertise to optimize cardiovascular risk reduction. 1

• Patients who develop significant adverse effects from fenofibrate (persistent elevation of transaminases >3× upper limit of normal, severe myopathy, or renal dysfunction with eGFR declining to <30 mL/min/1.73 m²) and still have triglycerides ≥500 mg/dL require specialist consultation for alternative pancreatitis-prevention strategies. 1, 2

Complex Metabolic Scenarios

• Patients with severe hypertriglyceridemia (≥500 mg/dL) and concurrent severe hepatic steatosis or cirrhosis should be referred because fenofibrate dosing and safety require careful monitoring, and alternative approaches may be needed to balance pancreatitis risk against hepatotoxicity concerns. 1, 2

• Pregnant women with severe hypertriglyceridemia (≥500 mg/dL) require immediate referral to a high-risk obstetrics team and lipid specialist because most lipid-lowering medications are contraindicated in pregnancy, and specialized dietary interventions or plasmapheresis may be necessary to prevent gestational pancreatitis. 2, 3

Practical Referral Algorithm

Step 1: Classify Triglyceride Severity

• Mild (150-199 mg/dL): Manage in primary care with lifestyle modifications and statin therapy if 10-year ASCVD risk ≥7.5% or diabetes age 40-75 years; no routine referral needed unless patient has established ASCVD with residual risk. 1, 2

• Moderate (200-499 mg/dL): Manage in primary care with statin therapy, lifestyle optimization for 3 months, then add icosapent ethyl if criteria met (established ASCVD or diabetes with ≥2 additional risk factors) or fenofibrate if criteria not met; refer if triglycerides remain >200 mg/dL after 6 months of maximal therapy or if strong family history of premature ASCVD. 1, 2

• Severe (500-999 mg/dL): Initiate fenofibrate immediately, implement extreme dietary fat restriction (20-25% of calories), eliminate all added sugars and alcohol, and aggressively treat secondary causes; refer if triglycerides remain ≥500 mg/dL after 3 months or if patient develops pancreatitis. 1, 2

• Very Severe (≥1000 mg/dL): Refer urgently to cardiology/lipid specialist or consider hospitalization if symptomatic (abdominal pain, nausea, vomiting) because intravenous insulin or plasmapheresis may be required. 1, 2, 3

Step 2: Assess for Secondary Causes

• Before referral, systematically evaluate and optimize: uncontrolled diabetes (target HbA1c <7%), hypothyroidism (check TSH), excessive alcohol intake (complete abstinence if triglycerides ≥500 mg/dL), offending medications (thiazides, beta-blockers, estrogen, corticosteroids, antiretrovirals, antipsychotics), chronic kidney disease (eGFR, proteinuria), and hepatic steatosis (AST/ALT, imaging). Correcting these factors can lower triglycerides by 20-50% independent of lipid-lowering drugs. 1, 2

Step 3: Document Maximal Therapy

• Ensure the following have been attempted for ≥3 months before referral: fenofibrate 54-160 mg daily (dose-adjusted for renal function), high-intensity statin if LDL-C elevated (atorvastatin 40-80 mg or rosuvastatin 20-40 mg), dietary fat restriction appropriate to triglyceride severity, 5-10% weight loss (or documented weight loss attempt), ≥150 minutes/week moderate-intensity aerobic activity, elimination of added sugars and alcohol, and optimization of all secondary causes. 1, 2

Step 4: Identify High-Risk Features Requiring Specialist Input

• Refer immediately if any of the following are present: triglycerides ≥1000 mg/dL, triglycerides ≥500 mg/dL after 3 months of maximal therapy, established ASCVD with triglycerides ≥150 mg/dL on high-intensity statin, suspected genetic hypertriglyceridemia (age <40 years, family history, xanthomas), intolerance to both statins and fibrates, or pregnancy with triglycerides ≥500 mg/dL. 1, 2, 5

Common Pitfalls to Avoid

• Do not delay referral while attempting multiple rounds of lifestyle modification alone in patients with triglycerides ≥500 mg/dL; the pancreatitis risk is immediate and requires pharmacologic intervention alongside lifestyle changes. 1, 2

• Do not overlook secondary causes before referral; uncontrolled diabetes with HbA1c >9% can drive triglycerides to severe levels, and optimizing glycemic control may reduce triglycerides by 20-50% without additional lipid medications, potentially obviating the need for specialist referral. 1, 2

• Do not refer patients with mild-moderate hypertriglyceridemia (150-499 mg/dL) prematurely before completing at least 3 months of optimized statin therapy and lifestyle modifications unless they have established ASCVD with residual risk or suspected genetic disorders. 1, 2

• Do not assume all patients with triglycerides ≥150 mg/dL on statin therapy require referral; only those with established ASCVD or diabetes with ≥2 additional cardiovascular risk factors (hypertension, smoking, family history, age >50 years men/>60 years women, chronic kidney disease) meet criteria for icosapent ethyl, which can be initiated in primary care with appropriate monitoring for atrial fibrillation. 1, 2